よむ、つかう、まなぶ。
10参考資料１－２ 成人用肺炎球菌ワクチンファクトシート［4.9MB］ (42 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_70339.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会（第64回 2／12）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults
60-64 years of age. Vaccine 2014; 32(20): 2364-74.
127.
Buchwald UK, Andrews CP, Ervin J, et al. Sequential administration of Prevnar 13™ and
PNEUMOVAX™ 23 in healthy participants 50 years of age and older. Hum Vaccin Immunother 2021; 17(8):
2678-90.
128.
Azuma M, Oishi K, Akeda Y, et al. Safety and immunogenicity of sequential administration of PCV13
followed by PPSV23 in pneumococcal vaccine-naïve adults aged ≥ 65 years: Comparison of booster effects
based on intervals of 0.5 and 1.0 year. Vaccine 2023; 41(5): 1042-9.
129.
Kawakami K, Ohkusa Y, Kuroki R, et al. Effectiveness of pneumococcal polysaccharide vaccine
against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine
2010; 28(43): 7063-9.
130.
Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in
preventing pneumonia and improving survival in nursing home residents: double blind, randomised and
placebo controlled trial. BMJ 2010; 340: c1004.
131.
Katoh S, Suzuki M, Ariyoshi K, Morimoto K. Serotype Replacement in Adult Pneumococcal
Pneumonia after the Introduction of Seven-Valent Pneumococcal Conjugate Vaccines for Children in Japan: a
Systematic Literature Review and Pooled Data Analysis. Jpn J Infect Dis 2017; 70(5): 495-501.
132.
Suzuki M, Dhoubhadel BG, Ishifuji T, et al. Serotype-specific effectiveness of 23-valent
pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a
multicentre, prospective, test-negative design study. Lancet Infect Dis 2017; 17(3): 313-21.
133.
Shimbashi R, Suzuki M, Chang B, et al. Effectiveness of 23-Valent Pneumococcal Polysaccharide
Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017. Emerg Infect Dis 2020; 26(10):
2378-86.
134.
Suzuki K, Kondo K, Washio M, et al. Preventive effects of pneumococcal and influenza vaccines on
community-acquired pneumonia in older individuals in Japan: a case-control study. Hum Vaccin Immunother
2019; 15(9): 2171-7.
135.
Nakashima K, Suzuki K, Aoshima M, et al. Effectiveness of the 23-valent pneumococcal
polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of
childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in
Japan. Vaccine 2022; 40(46): 6589-98.
136.
Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in
adults. Cochrane Database Syst Rev 2013; 2013(1): Cd000422.
137.
Latifi-Navid H, Latifi-Navid S, Mostafaiy B, Jamalkandi SA, Ahmadi A. Pneumococcal Disease and
the Effectiveness of the PPV23 Vaccine in Adults: A Two-Stage Bayesian Meta-Analysis of Observational and
RCT Reports. Sci Rep 2018; 8(1): 11051.
138.
Farrar JL, Childs L, Ouattara M, et al. Systematic Review and Meta-Analysis of the Efficacy and
Effectiveness of Pneumococcal Vaccines in Adults. Pathogens 2023; 12(5).
139.
Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal
42
60-64 years of age. Vaccine 2014; 32(20): 2364-74.
127.
Buchwald UK, Andrews CP, Ervin J, et al. Sequential administration of Prevnar 13™ and
PNEUMOVAX™ 23 in healthy participants 50 years of age and older. Hum Vaccin Immunother 2021; 17(8):
2678-90.
128.
Azuma M, Oishi K, Akeda Y, et al. Safety and immunogenicity of sequential administration of PCV13
followed by PPSV23 in pneumococcal vaccine-naïve adults aged ≥ 65 years: Comparison of booster effects
based on intervals of 0.5 and 1.0 year. Vaccine 2023; 41(5): 1042-9.
129.
Kawakami K, Ohkusa Y, Kuroki R, et al. Effectiveness of pneumococcal polysaccharide vaccine
against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine
2010; 28(43): 7063-9.
130.
Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in
preventing pneumonia and improving survival in nursing home residents: double blind, randomised and
placebo controlled trial. BMJ 2010; 340: c1004.
131.
Katoh S, Suzuki M, Ariyoshi K, Morimoto K. Serotype Replacement in Adult Pneumococcal
Pneumonia after the Introduction of Seven-Valent Pneumococcal Conjugate Vaccines for Children in Japan: a
Systematic Literature Review and Pooled Data Analysis. Jpn J Infect Dis 2017; 70(5): 495-501.
132.
Suzuki M, Dhoubhadel BG, Ishifuji T, et al. Serotype-specific effectiveness of 23-valent
pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a
multicentre, prospective, test-negative design study. Lancet Infect Dis 2017; 17(3): 313-21.
133.
Shimbashi R, Suzuki M, Chang B, et al. Effectiveness of 23-Valent Pneumococcal Polysaccharide
Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017. Emerg Infect Dis 2020; 26(10):
2378-86.
134.
Suzuki K, Kondo K, Washio M, et al. Preventive effects of pneumococcal and influenza vaccines on
community-acquired pneumonia in older individuals in Japan: a case-control study. Hum Vaccin Immunother
2019; 15(9): 2171-7.
135.
Nakashima K, Suzuki K, Aoshima M, et al. Effectiveness of the 23-valent pneumococcal
polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of
childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in
Japan. Vaccine 2022; 40(46): 6589-98.
136.
Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in
adults. Cochrane Database Syst Rev 2013; 2013(1): Cd000422.
137.
Latifi-Navid H, Latifi-Navid S, Mostafaiy B, Jamalkandi SA, Ahmadi A. Pneumococcal Disease and
the Effectiveness of the PPV23 Vaccine in Adults: A Two-Stage Bayesian Meta-Analysis of Observational and
RCT Reports. Sci Rep 2018; 8(1): 11051.
138.
Farrar JL, Childs L, Ouattara M, et al. Systematic Review and Meta-Analysis of the Efficacy and
Effectiveness of Pneumococcal Vaccines in Adults. Pathogens 2023; 12(5).
139.
Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal
42